Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5134 - Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Vikas Prasad

Citation

Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293

Authors

V. Prasad1, R. Srirajaskanthan2, C.M. Grana3, S. Baldari4, T. Shah5, A. Lamarca6, F. Courbon7, K. Scheidhauer8, E. Baudin9, X. Truong-Thanh10, A. Houchard11, L. Bodei12

Author affiliations

  • 1 Department Of Nuclear Medicine, Universitaetsfrauenklinik Ulm, 89075 - Ulm/DE
  • 2 Gastroenterology And Neuroendocrine Cancers, Kings College Hospital, London/GB
  • 3 Nuclear Medicine, European Institute of Oncology, Milan/IT
  • 4 Nuclear Medicine Unit, University of Messina, Messina/IT
  • 5 Hepatocellular Carcinoma/neuroendocrine Tumours, Queen Elizabeth Hospital Birmingham, Birmingham/GB
  • 6 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 7 Nuclear Medicine, Institut Claudius Regaud, 31059 - Toulouse/FR
  • 8 Klinikum R.d. Isar, Technical University Muenchen, Munich/DE
  • 9 Institut De Cancérologie, Gustave Roussy, 94805 - Villejuif/FR
  • 10 Global Medical Affairs, Ipsen Pharma France, 92100 - Boulogne-Billancourt/FR
  • 11 Clinical Statistics, Ipsen Pharma France, 92100 - Boulogne-Billancourt/FR
  • 12 Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
More

Resources

Abstract 5134

Background

177Lu-DOTATATE is licensed for gastroenteropancreatic (GEP-)NETs. PRELUDE is an international retrospective study (NCT02788578) to describe LAN use with 177Lu-PRRT (LAN–PRRT) in advanced NETs. Here we report effectiveness results, including a post hoc TGR analysis to complement RECIST-based progression measures.

Methods

Analysis of patients (pts) receiving LAN with 177Lu-DOTATATE/DOTATOC followed by LAN only. Key inclusion criteria: metastatic/locally advanced, grade 1/2, somatostatin receptor-positive GEP-/lung NET, progressive disease (PD) within 12 mo and within 6 mo before LAN–PRRT start (assessed locally), ≥1 LAN injection 8 wks before LAN–PRRT start, continuous LAN use during LAN–PRRT, cumulative PRRT activity ≥500 mCi. Primary endpoint: progression-free survival (PFS) rate at end of last LAN–PRRT cycle (RECIST v1.1, central review). Key secondary endpoints: PFS rate at last available follow-up (RECIST v1.1 central review), best overall response (OR; RECIST v1.1 central review). Post hoc analysis: TGR (% variation of tumour volume/mo) calculated from sum of longest diameter of target lesions between two MRI/CT scans during: prebaseline/baseline (within 12 mo and within 6 mo before baseline), baseline/end of last LAN–PRRT cycle (within 6 mo before baseline and end of last LAN–PRRT cycle), and end of last LAN–PRRT cycle/last available follow-up visit.

Results

Enrolment terminated early (insufficient recruitment): 40 pts (GEP n = 39; lung n = 1) (full analysis set: GEP n = 23, lung n = 1). LAN exposure and effectiveness results in GEP-NETs are shown in the table. Waterfall plots of prebaseline/baseline TGR showed individual progressions and regressions, with a mean of 0 [–1.4; 1.5].Table: 1331P

Patients with GEP-NETs (n = 23)
Median (range) LAN exposure, mo Overall Prior to LAN–PRRT During LAN–PRRT During LAN only follow-up37.0 (16.7–90.0) 10.5 (0.7–61.7) 14.2 (7.0–24.0) 12.6 (6.1–32.5)
PFS rate [95% CI] at end of last LAN–PRRT cycle91.7% [53.9; 98.8]
PFS rate [95% CI] at last available follow-up (up to 12 mo post-treatment)95.0% [69.5; 99.3]
Best OR [95% CI] RECIST v1.1Partial response (PR): 34.8% [18.8; 55.1] Stable disease: 60.9% [40.8; 77.8] PD: 4.3% [0.8; 21.0]
Mean [95% CI] TGR: Prebaseline/baseline Baseline/end of last LAN–PRRT cycle End of last LAN–PRRT cycle/last available follow-up visit0.0% [–1.4; 1.5] –1.6% [–2.7; –0.4] –0.2% [–1.3; 0.9]

Conclusions

Effectiveness data were encouraging in this small selected population. TGR suggested tumour regression during LAN–PRRT. Despite low baseline TGR, 35% pts had RECIST PR on central assessment.

Clinical trial identification

PRELUDE: NCT02788578.

Legal entity responsible for the study

Ipsen.

Funding

Ipsen.

Editorial Acknowledgement

Writing and editorial/submission support provided by Tom Vizard, PhD, and Richard McDonald (Watermeadow Medical), funded by Ipsen.

Disclosure

V. Prasad: Honoraria: Bayer, Ipsen, ITG; Consultant: Bayer, Ipsen, ITG. C.M. Grana: Consultant: Norgine; Other: Ipsen, Novartis, Iason. T. Shah: Honoraria: Ipsen; Consultant: Ipsen. A. Lamarca: Speaker's bureaux: Ipsen. F. Courbon: Advisory board member: Norgine; Grant recipient: AAA, Bayer; Speaker's bureaux: AAA, Bayer, GEHC, Ipsen, Novartis; Other: Cyclopharma. K. Scheidhauer: Honoraria: Ipsen, Shire. Consultant: Eisa, Ipsen, Novartis, Shire. E. Baudin: Honoraria: Ipsen, Novartis, Pfizer; Consultant, Grant recipient: AAA, Ipsen, Novartis, Pfizer. X.-M. Truong-Thanh: Employee, Stock owner: Ipsen. A. Houchard: Grant recipient, Employee, Stock owner: Ipsen. L. Bodei: Honoraria, Consultant, Speaker's bureaux: AAA, Ipsen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings